Entera Bio Ltd.

Proxy statement on Schedule 14A (the “Proxy Statement”) previously filed with the Securities and Exchange Commission (the “Commission”) on June 3, 2026.

The foregoing description of the Amendment is only a summary and is qualified in its entirety by the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.

At the Annual Meeting, the Company’s shareholders approved an amendment (the “Articles Amendment”) to the Company’s Amended and Restated Articles of Association (as amended, the “Articles”) to increase the number of authorized Ordinary Shares from 140,010,000 to 350,000,000. The Articles Amendment became effective upon approval by the Company’s shareholders at the Annual Meeting. The foregoing description of the Amendment is only a summary and is qualified in its entirety by the full text of the Articles, which are filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.03.

The Company held its 2026 Annual Meeting of Shareholders on July 14, 2026 (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of the Company’s shareholders at the Annual Meeting are as follows:

Proposal 1a: Election of Sean Ellis to the Board of Directors of the Company as a Class III director for a three-year term to hold office until the Company’s 2029 Annual Meeting of Shareholders:

Proposal 1b: Election of Steven D. Rubin to the Board of Directors of the Company as a Class III director for a three-year term to hold office until the Company’s 2029 Annual Meeting of Shareholders:

Proposal 1c: Election of Geno H. Germano to the Board of Directors of the Company as a Class III director for a three-year term to hold office until the Company’s 2029 Annual Meeting of Shareholders:

Proposal 2: